BioTuesdays
Feature

In conversation with Kevin Smith

As the newly appointed chief commercial officer of closely-held Sensium Healthcare, a pioneer in wireless monitoring of patient vital signs, Kevin Smith is in charge of developing and executing the company’s global...

December 15, 2015
Feature

Oramed sees value creating events through 2016

By Len Zehr Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for...

December 1, 2015
Feature

Concert starts multiple dose trial with CF drug

By Len Zehr Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation...

November 17, 2015
Feature

Viking Therapeutics to complete two POC trials in 2016

By Len Zehr Viking has successfully completed three Phase 1 studies with VK5211, including a 21-day ascending dose study. Viking Therapeutics (NASDAQ:VKTX) expects to complete two proof-of-concept Phase 2 trials in 2016...

November 10, 2015
Feature

CRH Medical to consolidate GI anesthesia market

By Len Zehr With four acquisitions and a joint venture under its belt over the past 10 months, CRH Medical (NYSE MKT:CRHM; TSX:CRH) is in talks to continue consolidating the large and fragmented market of...

October 27, 2015
Feature

In conversation with Arun Menawat

As president and CEO of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ), Arun Menawat has led the company through a strategic transformation this year into a direct sales company from one originally dependent on partners to...

October 20, 2015
Feature

In conversation with Gagan Gill

By Len Zehr As CEO of closely-held SIGMA Surgical, an upstart data-analytics company, Gagan Gill has a passion for entrepreneurial adventure and startup culture. After stints in sales and marketing in the medical...

September 29, 2015
Feature

In conversation with Geoffrey Hamilton-Fairley

As CEO of closely-held Oncimmune, an early cancer diagnostic company in Britain, Geoffrey Hamilton-Fairley has had a personal commitment to cancer detection. His father was the first medical oncologist in the UK and an...

September 15, 2015
Feature

Hydra Biosciences to have Phase 1 TRPA1 data soon

By Len Zehr Closely-held Hydra Biosciences expects to complete Phase 1 trials of its HX-100 inhibitor of the Transient Receptor Potential (TRPA1) ion channel as a treatment for painful diabetic neuropathy and allergic...

September 1, 2015
Feature

Peritech readies U.S. launch of novel hemorrhoid gel

By Len Zehr Closely-held Peritech Pharma of Israel is in discussions with potential marketing partners for a U.S. launch of its once-daily over-the-counter gel, now known as PP-110, for the treatment of hemorrhoids. “PP...

August 24, 2015
Feature

Cellectar Biosciences refocusing on therapeutics

After completing a strategic review of its cancer therapeutic and cancer diagnostic assets, Cellectar Biosciences (NASDAQ:CLRB) has refocused the company on its phospholipid ether drug conjugate (PDC) platform and...

August 18, 2015
Feature

In conversation with Nicole Grannell

By Len Zehr As vice-president of business development for Bay Area Research Logistics (BARL), a specialized clinical trial design, packaging and logistics firm, Nicole Grannell manages the logistical components of...

August 4, 2015
Matinas BioPharma Holdings
Feature

Matinas BioPharma moves focus to anti-infectives

By Len Zehr After moving a novel omega-3 program through a successful Phase 2 program, Matinas BioPharma Holdings (OTCQB:MTNB) is now advancing two anti-infective drug candidates in the war against drug resistance. “Our...

July 28, 2015
Feature

In conversation with Heather Morehouse Ettinger

By Len Zehr As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and...

July 14, 2015